The High Health Authority (HAS) validated this Thursday, November 21, the vaccine developed by the Moderna group against the main virus that causes bronchiolitis so that it has its place among other vaccines to protect older people against this respiratory syncytial virus (RSV). .
In its recommendation, the HAS considers that “the mRESVIA vaccine can be used, like other RSV vaccines, within the framework of the current vaccination strategy against RSV infections in adults, that is, in people aged 75 years or older. more and in people aged 65 years. and more so with chronic respiratory or cardiac pathologies.
The HAS does not take a position, for the moment, on the relevance and need to repeat vaccination after a first injection. To simplify the vaccination process, he believes that “the mRESVIA vaccine can be administered concomitantly with the flu and Covid-19 vaccines.”
Two other vaccines can also be used.
HAS recommends rapidly conducting studies to evaluate the effectiveness and real-life impact of the mRESVIA vaccine on RSV hospitalizations and to evaluate its effectiveness in people aged 80 years and older and in immunocompromised people.
Two other vaccines against RSV (Arexvy from the GSK laboratory and Abrysvo from the Pfizer laboratory) may be used as part of this vaccination strategy for older people.
The mRESVIA vaccine is a Moderna messenger RNA vaccine aimed at people over 60 years of age and which received European marketing authorization (MAA) in August 2024.
Source: BFM TV
